Legal & General Group’s Kindred Biosciences, Inc. KIN Stock Holding History

Legal & General Group’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,262	Closed	-$21K	–	3751
2021 Q1	$21K	Hold	4,262	–	–	﹤0.01%	3124
2020 Q4	$18K	Hold	4,262	–	–	﹤0.01%	3149
2020 Q3	$18K	Sell	4,262 -1,838	-30%	-$7.68K	﹤0.01%	3013
2020 Q2	$27K	Sell	6,100 -224	-4%	-$1K	﹤0.01%	2945
2020 Q1	$25K	Sell	6,324 -1,152	-15%	-$9.78K	﹤0.01%	2842
2019 Q4	$63K	Buy	7,476 +1,446	+24%	+$11.3K	﹤0.01%	2731
2019 Q3	$41K	Hold	6,030	–	–	﹤0.01%	2825
2019 Q2	$50K	Hold	6,030	–	–	﹤0.01%	2782
2019 Q1	$55K	Buy	6,030 +1,371	+29%	+$13.9K	﹤0.01%	2686
2018 Q4	$51K	Hold	4,659	–	–	﹤0.01%	2687
2018 Q3	$65K	Buy	4,659 +920	+25%	+$12.4K	﹤0.01%	2653
2018 Q2	$40K	Sell	3,739 -954	-20%	-$9.3K	﹤0.01%	2869
2018 Q1	$41K	Hold	4,693	–	–	﹤0.01%	2846
2017 Q4	$44K	Hold	4,693	–	–	﹤0.01%	2913
2017 Q3	$37K	Buy	4,693 +1,587	+51%	+$11.9K	﹤0.01%	3008
2017 Q2	$28K	Buy	+3,106	New	+$22.3K	﹤0.01%	3068

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Legal & General Group's KIN Position: Q2 2021 in Review

Legal & General Group sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 4,262 shares — an estimated $21K sold.

Legal & General Group first reported a position in KIN in Q2 2017 and held it in 16 quarters. The position peaked at $65K in Q3 2018. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

Legal & General Group reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Legal & General Group sold 4,262 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $21K.
Legal & General Group first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 16 quarters.
Legal & General Group's Kindred Biosciences, Inc. position peaked at $65K in Q3 2018.
87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.